Your browser doesn't support javascript.
loading
Long Receptor Residence Time of C26 Contributes to Super Agonist Activity at the Human ß2 Adrenoceptor.
Rosethorne, Elizabeth M; Bradley, Michelle E; Gherbi, Karolina; Sykes, David A; Sattikar, Afrah; Wright, John D; Renard, Emilie; Trifilieff, Alex; Fairhurst, Robin A; Charlton, Steven J.
Affiliation
  • Rosethorne EM; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen's Medical Centre, University of Nottingham,
  • Bradley ME; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen's Medical Centre, University of Nottingham,
  • Gherbi K; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen's Medical Centre, University of Nottingham,
  • Sykes DA; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen's Medical Centre, University of Nottingham,
  • Sattikar A; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen's Medical Centre, University of Nottingham,
  • Wright JD; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen's Medical Centre, University of Nottingham,
  • Renard E; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen's Medical Centre, University of Nottingham,
  • Trifilieff A; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen's Medical Centre, University of Nottingham,
  • Fairhurst RA; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen's Medical Centre, University of Nottingham,
  • Charlton SJ; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (E.M.R., M.E.B., K.G., D.A.S., A.S., J.D.W., S.J.C.); Novartis Institutes for Biomedical Research, Basel, Switzerland (E.R., A.T., R.A.F.); and School of Life Sciences, Queen's Medical Centre, University of Nottingham,
Mol Pharmacol ; 89(4): 467-75, 2016 Apr.
Article in En | MEDLINE | ID: mdl-26772612
ABSTRACT
Super agonists produce greater functional responses than endogenous agonists in the same assay, and their unique pharmacology is the subject of increasing interest and debate. We propose that receptor residence time and the duration of receptor signaling contribute to the pharmacology of super agonism. We have further characterized the novel ß2 adrenoceptor agonist C26 (7-[(R)-2-((1R,2R)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone), which displays higher intrinsic activity than the endogenous ligand adrenaline in cAMP accumulation, ß-arrestin-2 recruitment, and receptor internalization assays. C26 recruited ß-arrestin-2, and internalized the Green Fluorescent Protein (GFP)-taggedß2 adrenoceptor at a slow rate, with half-life (t1/2) values of 0.78 ± 0.1 and 0.78 ± 0.04 hours, respectively. This was compared with 0.31 ± 0.04 and 0.34 ± 0.01 hours for adrenaline-mediated ß-arrestin-2 recruitment and GFP-ß2 internalization, respectively. The slower rate for C26 resulted in levels of ß-arrestin-2 recruitment increasing up to 4-hour agonist incubation, at which point the intrinsic activity was determined to be 124.3 ± 0.77% of the adrenaline response. In addition to slow functional kinetics, C26 displayed high affinity with extremely slow receptor dissociation kinetics, giving a receptor residence half-life of 32.7 minutes at 37°C, which represents the slowest dissociation rate we have observed for any ß2 adrenoceptor agonist tested to date. In conclusion, we propose that the gradual accumulation of long-lived active receptor complexes contributes to the increased intrinsic activity of C26 over time. This highlights the need to consider the temporal aspects of agonist binding and signaling when characterizing ligands as super agonists.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Adrenergic, beta-2 / Adrenergic beta-2 Receptor Agonists Limits: Animals / Humans / Male Language: En Journal: Mol Pharmacol Year: 2016 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Adrenergic, beta-2 / Adrenergic beta-2 Receptor Agonists Limits: Animals / Humans / Male Language: En Journal: Mol Pharmacol Year: 2016 Document type: Article
...